J
Jose Miguel Sanchez
Researcher at University of Texas MD Anderson Cancer Center
Publications - 29
Citations - 9465
Jose Miguel Sanchez is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 15, co-authored 26 publications receiving 8751 citations. Previous affiliations of Jose Miguel Sanchez include Autonomous University of Barcelona & University of Zaragoza.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell,Teresa Moran,Cristina Queralt,Rut Porta,Felipe Cardenal,Carlos Camps,Margarita Majem,Guillermo Lopez-Vivanco,Dolores Isla,Mariano Provencio,A. Insa,Bartomeu Massuti,José Luis González-Larriba,Luis Paz-Ares,Isabel Bover,Rosario García-Campelo,Miguel Angel Moreno,Silvia Catot,Christian Rolfo,Noemi Reguart,Ramon Palmero,Jose Miguel Sanchez,Roman Bastus,Clara Mayo,Jordi Bertran-Alamillo,Miguel Angel Molina,Jose Javier Sanchez,Miquel Taron +27 more
TL;DR: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment, and the association between the mutations and the outcome of erlotinib treatment is analyzed.
Journal Article
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Reginald V. Lord,Jan Brabender,David R. Gandara,Vicente Alberola,Carlos Camps,Manuel Domine,Felip Cardenal,Jose Miguel Sanchez,Paul H. Gumerlock,Miquel Taron,Jose Javier Sanchez,K. D. Danenberg,Peter V. Danenberg,Rafael Rosell +13 more
TL;DR: Everexpression of the excision repair cross-complementing 1 (ERCC1) gene is a predictive factor for survival after CDDP/Gem therapy in advanced NSCLC and the presence of weight loss were significant prognostic factors for survival in a Cox proportional hazards multivariable analysis.
Journal ArticleDOI
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
M. Cobo,Dolores Isla,Bartomeu Massuti,Ana Montes,Jose Miguel Sanchez,Mariano Provencio,Nuria Viñolas,Luis Paz-Ares,Guillermo Lopez-Vivanco,Miguel Angel Muñoz,Enriqueta Felip,Vicente Alberola,Carlos Camps,Manuel Domine,Jose Javier Sanchez,Maria Sanchez-Ronco,K. D. Danenberg,Miquel Taron,David R. Gandara,Rafael Rosell +19 more
TL;DR: Assessment of ERCC1 mRNA expression in patient tumor tissue is feasible in the clinical setting and predicts response to docetaxel and cisplatin, and a multibiomarker profile predictive of patient outcome is refined.
Journal ArticleDOI
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas
Miguel Taron,Yukito Ichinose,Rafael Rosell,Tony Mok,Bartomeu Massuti,Lurdes Zamora,Jose Luis Mate,Christian Manegold,Mayumi Ono,Cristina Queralt,Thierry Jahan,Jose Javier Sanchez,Maria Sanchez-Ronco,Victor Hsue,David M. Jablons,Jose Miguel Sanchez,Teresa Moran +16 more
TL;DR: The presence of EG FR mutations is a major determinant of gefitinib response, and targeting EGFR should be considered in preference to chemotherapy as first-line treatment in lung adenocarcinomas that have demonstrable EGFR mutations.